Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Exenatide in the context of insulin resistance, prediabetes & type 2 diabetes.

Positron emission tomography was used to determine the effect of exenatide on MGU and MBF during a pituitary-pancreatic hyperglycemic clamp with (18)F-fluorodeoxyglucose and (13)N-ammonia as tracers.

Who Took Part

According to the abstract, 2 patients were involved.

The age groups tagged for this paper are middle-aged adults, men only.

The researchers conducted a randomized, double-blinded, placebo-controlled crossover study in eight male, insulin-naive, type 2 diabetes mellitus patients without coronary artery disease.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The patients were allocated by chance, so the Exenatide group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Exenatide.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

Each person switched between Exenatide and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Biological Transport, Coronary Circulation, Diabetes Mellitus, Type 2, Exenatide, Glucose, Heart and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 2 patients in people with insulin resistance, prediabetes & type 2 diabetes.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exenatide compound page, Insulin resistance, prediabetes & type 2 diabetes research.